<DOC>
	<DOCNO>NCT00232856</DOCNO>
	<brief_summary>The main objective study assess safety effectiveness Cypher™ sirolimus-eluting stent reduce angiographic in-lesion late loss patient in-stent restenotic native coronary artery lesion .</brief_summary>
	<brief_title>A Study Cypher SES Treat Restenotic Native Coronary Artery Lesions .</brief_title>
	<detailed_description>This multicenter ( 11 site ) , non-randomized study . Patients meet eligibility criterion treat Cypher™ sirolimus-eluting stent . All patient repeat angiography six month post-procedure additionally follow clinically 1 , 6 9 month 3 year . The result study compare outcome GAMMA I / II historical control .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . The patient instent restenosis ≥ 60 % &lt; 100 % ( QCA online MLD compare distal reference diameter ) native coronary artery . 2 . The study target lesion locate vessel contain another lesion require treatment . Lesions locate vessel may treat percutaneous revascularization time procedure , BUT must successfully treat prior treatment study target lesion . 1 . Unprotected leave main coronary disease ≥ 50 % stenosis ; 2 . Patient previously treat brachytherapy coronary vessel . 3 . Target lesion involve bifurcation include side branch &gt; 2.5mm diameter . 4 . The patient sustain recent ( &lt; 72 hour ) myocardial infarction define serum CK 2x upper limit normal elevate MB abnormal lab value .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>